Bilal Hameed, MD
Transplant Hepatology · San Francisco, CANPI 1114037421
Payments from drug & device makers
Across 435 payments — averaging $2811.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intercept Pharmaceuticals, Inc.$559K
- Gilead$327K
- Madrigal Pharmaceuticals$175K
- Bausch Health US, LLC$82K
- Intercept Pharma Europe Ltd.$58K
- Dova Pharmaceuticals$11K
- plus $11K from 5 others
What the payments were for
- Consulting fees$27,27862%
- Speaking & faculty fees$4,58310%
- Travel & lodging$10,27924%
- Food & beverage$1,5163%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intercept Pharmaceuticals, Inc. | 102 | $559,357 |
| Gilead | 73 | $327,117 |
| Madrigal Pharmaceuticals | 50 | $174,849 |
| Bausch Health US, LLC | 17 | $82,025 |
| Intercept Pharma Europe Ltd. | 8 | $57,766 |
| Dova Pharmaceuticals | 1 | $10,931 |
| Mallinckrodt Hospital Products Inc. | 3 | $6,125 |
| Novo Nordisk | 1 | $2,713 |
| Novo Nordisk AS | 177 | $1,953 |
| Ipsen Biopharmaceuticals, Inc | 2 | $196 |
| AbbVie | 1 | $109 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- REZDIFFRA$12,951
- OCALIVA$248
- RESMETIROM$136
- IQIRVO$115
- Mavyret$109
How this compares
$1,223,140 in reported general payments places this provider in the 90th percentile of 39 transplant hepatology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XifaxanRifaximin | 16 | $53,436 |
| BaracludeEntecavir | 12 | $16,353 |
| Ursodiol | 55 | $9,915 |
| Entecavir | 21 | $8,251 |
| Azathioprine | 44 | $3,829 |
| Lactulose | 12 | $499 |
| Carvedilol | 39 | $294 |
| Ciprofloxacin Hcl | 17 | $243 |
| Prednisone | 34 | $211 |
| Furosemide | 20 | $167 |
| Trazodone Hcl | 15 | $162 |
| Spironolactone | 18 | $71 |
Paid to pharmacies, not to this prescriber.
Other transplant hepatology in San Francisco
- Kidist YimamSan Francisco$428K
- Danielle BrandmanSan Francisco$350K
- Raphael MerrimanSan Francisco$286K
- Jennifer LaiSan Francisco$262K
- Jennifer PriceSan Francisco$212K
- Edward HoltSan Francisco$152K
- Chanda HoSan Francisco$3K
- Jin GeSan Francisco$2K
- Jennifer GuySan Francisco$245
- Adil WakilSan Francisco$96
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.